First UK real-world study shows promise for sacituzumab govitecan in metastatic breast cancer

FHS
April 26, 2024
10:42 am

The real-world safety and efficacy of sacituzumab govitecan (SG) against metastatic triple-negative breast cancer.

AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trial – Pharmaceutical Technology

Tezspire is a thymic stromal lymphopoietin (TSLP) inhibiting monoclonal antibody, which generated $86m in sales in 2023. Image credit: eamesBot / Shutterstock. AstraZeneca and Amgen

November 8, 2024

COVID-19 vaccination before first infection may reduce risk of developing long COVID

Receiving at least one dose of a covid-19 vaccine before the first infection is strongly associated with a reduced risk of developing post-covid-19 condition, commonly

November 23, 2023

Chemotherapy/ICI Combos Falter as Second-Line Treatment for Gastric Cancer

Combining chemotherapy with one or two immune checkpoint inhibitors (ICIs) as second-line treatment for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma failed to improve progression-free

April 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.